“Ipsen is navigating temporary headwind pressures including Chinese macroeconomic weakness, currency headwinds, and specific shipping delays for Carbometyx. The manager remains highly optimistic about its long-term outlook, given its global distribution network and a deep pipeline of twenty clinical-stage drugs.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.